Umbilical cord stem cells as regenerative therapy: advances in the treatment of type I diabetes

Daniela Villada Escobar and Karina Bustamante Galarza

SCT Proceedings in Interdisciplinary Insights and Innovations, 2025, vol. 3, 10.56294/piii2025575

Abstract: Type I diabetes mellitus was presented as an autoimmune disease that destroyed the β cells of the pancreas, generating an insulin deficit and metabolic complications. Although traditional insulin treatment was necessary, it failed to stop the progression of the disease. Regenerative medicine offered new alternatives, including the use of stem cells derived from the umbilical cord. These cells showed an ability to differentiate into pancreatic cells and modulate the immune system, which helped to improve glycaemic control and reduce dependence on exogenous insulin. Clinical studies confirmed that this therapy was safe, well-tolerated and ethically acceptable, making it a promising alternative in the treatment of T1D.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:procee:v:3:y:2025:i::p:1056294piii2025575:id:1056294piii2025575

Access Statistics for this article

More articles in SCT Proceedings in Interdisciplinary Insights and Innovations from AG Editor (Argentina)
Bibliographic data for series maintained by Javier Gonzalez-Argote ().